Prescribing menopausal hormone therapy: an evidence-based approach
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The constantly changing landscape regarding menopausal hormone therapy (MHT) has been challenging for providers caring for menopausal women. After a decade of fear and uncertainty regarding MHT, reanalysis of the Women's Health Initiative data and the results of recent studies have provided some clarity regarding the balance of risks and benefits of systemic MHT. Age and years since menopause are now known to be important variables affecting the benefit-risk profile. For symptomatic menopausal women who are under 60 years of age or within 10 years of menopause, the benefits of MHT generally outweigh the risks. Systemic MHT initiated early in menopause appears to slow the progression of atherosclerotic disease, thereby reducing the risk of cardiovascular disease and mortality. During this window of opportunity, MHT might also provide protection against cognitive decline. In older women and women more than 10 years past menopause, the risk-benefit balance of MHT is less favorable, particularly with regard to cardiovascular risk and cognitive impairment. For women entering menopause prematurely (<40 years), MHT ameliorates the risk of cardiovascular disease, osteoporosis, and cognitive decline. Nonoral administration of estrogen offers advantages due to the lack of first-pass hepatic metabolism, which in turn avoids the increased hepatic synthesis of clotting proteins, C-reactive protein, triglycerides, and sex hormone-binding globulin. The duration of combined MHT use is ideally limited to less than 5 years because of the known increase in breast cancer risk after 3-5 years of use. Limitations to use of estrogen only MHT are less clear, since breast cancer risk does not appear to increase with use of estrogen alone. For women under the age of 60 years, or within 10 years of onset of natural menopause, MHT for the treatment of bothersome menopausal symptoms poses low risk and is an acceptable option, particularly when nonhormonal management approaches fail.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shumaker, S. A., Legault, C., Rapp, S. R., Thal, L., Wallace, R. B., Ockene, J. K., Hendrix, S. L., Jones III, B. N., Assaf, A. R., Jackson, R. D., et al. (2003) · JAMA · doi:10.1001/jama.289.20.2651 · Cited by 2,178
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause
Rossouw, J. E., Prentice, R. L., Manson, J. E., Wu, L., Barad, D., Barnabei, V. M., Ko, M., LaCroix, A. Z., Margolis, K. L., & Stefanick, M. L. (2007) · JAMA · doi:10.1001/jama.297.13.1465 · Cited by 1,741
The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
Colditz, G. A., Hankinson, S. E., Hunter, D. J., Willett, W. C., Manson, J. E., Stampfer, M. J., Hennekens, C., Rosner, B., & Speizer, F. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506153322401 · Cited by 1,487
Fournier, A., Berrino, F., & Clavel-Chapelon, F. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9523-x · Cited by 693
Parker, W. H., Broder, M. S., Chang, E., Feskanich, D., Farquhar, C., Liu, Z., Shoupe, D., Berek, J. S., Hankinson, S., & Manson, J. E. (2009) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3181a11c64 · Cited by 640 · cited 1×
“33 35 Beyond the issue of age, the effect of MHT on stroke risk might vary by dose, route of administration, type of MHT, and the presence of risk factors such as hypertension.”
for the Women’s Health Initiative Investigators, Margolis, K. L., Bonds, D. E., Rodabough, R. J., Tinker, L., Phillips, L. S., Allen, C., Bassford, T., Burke, G., Torrens, J., et al. (2004) · Diabetologia · doi:10.1007/s00125-004-1448-x · Cited by 599 · cited 1×
“Diabetes In the WHI, use of MHT containing oral conjugated equine estrogens (CEE) alone or oral CEE plus progestin was found to be associated with a reduction in the development of type 2 diabetes.(21,22,27) There is conflicting information about whether a protective benefit of MHT against diabetes is mediated through…”
Canonico, M., Plu-Bureau, G., Lowe, G. D. O., & Scarabin, P.-Y. (2008) · BMJ · doi:10.1136/bmj.39555.441944.be · Cited by 569
Associations of depression with the transition to menopause
Freeman, E. W. (2010) · Menopause · doi:10.1097/gme.0b013e3181db9f8b · Cited by 331
Zhu, L., Brown, W. C., Cai, Q., Krust, A., Chambon, P., McGuinness, O. P., & Stafford, J. M. (2013) · Diabetes · doi:10.2337/db11-1718 · Cited by 326
Rocca, W. A., Grossardt, B. R., & Shuster, L. T. (2011) · Brain Research · doi:10.1016/j.brainres.2010.10.031 · Cited by 283 · cited 1×
“Studies in prematurely menopausal women have also supported the role of MHT in preventing cognitive decline and dementia.(49,50) By contrast, randomized controlled trials in older women, such as those included in the Women’s Health Initiative Memory Study, showed an increased risk of dementia in women aged 65 years an…”
Self-citationPremature menopause or early menopause and risk of ischemic stroke
Rocca, W. A., Grossardt, B. R., Miller, V. M., Shuster, L. T., & Brown, R. D. (2012) · Menopause · doi:10.1097/gme.0b013e31822a9937 · Cited by 188 · cited 1×
“For women with early estrogen deficiency due to premature onset of menopause, there is accumulating data on protection against stroke with the administration of estrogen following oophorectomy.(33) Early estrogen deprivation appears to increase a woman’s risk of stroke, and estrogen therapy may reduce this risk.”
Self-citationSleep in menopause: differential effects of two forms of hormone replacement therapy
Montplaisir, J., Lorrain, J., Denesle, R., & Petit, D. (2001) · Menopause · doi:10.1097/00042192-200101000-00004 · Cited by 156
Cited by
Asi, N., Mohammed, K., Haydour, Q., Gionfriddo, M. R., Vargas, O. L. M., Prokop, L. J., Faubion, S. S., & Murad, M. H. (2016) · Systematic Reviews · doi:10.1186/s13643-016-0294-5 · Cited by 114
Self-citationPreconception lifestyle advice for people with infertility
Boedt, T., Vanhove, A.-C., Vercoe, M. A., Matthys, C., Dancet, E., & Lie Fong, S. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008189.pub3 · Cited by 66
A randomized, double-blind, placebo-controlled trial of Schisandra chinensis for menopausal symptoms
Park, J. Y., & Kim, K. H. (2016) · Climacteric · doi:10.1080/13697137.2016.1238453 · Cited by 32
Metadata
- Authors
- Sood, R., Faubion, S., Kuhle, C., Thielen, J., & Shuster, L.
- Venue
- International Journal of Women's Health
- Publisher
- Informa UK Limited
- Published
- 2014-01
- Volume
- 6
- Pages
- 47
- ISSN
- 1179-1411 (ISSN-L)
- OpenAlex
- W2060689965
- Cited by
- 106
- References
- 12
- FWCI
- 8.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.